Close
FINDING CURES TOGETHER<sup>SM</sup>

Inaugural AACR International Meeting
Advances in Malignant Lymphoma:
Maximizing the Basic-Translational Interface for Clinical Application

​Program 

View online Proceedings and Itinerary Planner

Friday, June 22

Saturday, June 23

Sunday, June 24

Monday, June 25

Tuesday, June 26

Friday, June 22

Welcome and Opening Keynote Address 
6-8 p.m.

Welcome from AACR Chief Executive Officer
Margaret Foti, American Association for Cancer Research, Philadelphia, Pennsylvania

Welcome from Scientific Committee Chair
Ari M. Melnick, Weill Cornell Medical College, New York, New York

Keynote Address: Immunogenicity predicts prevention
Michael A. Caligiuri, City of Hope National Medical Center, Duarte, California

Keynote Address: CAR T for lymphoma and beyond
Carl H. June, University of Pennsylvania, Philadelphia, Pennsylvania

Panel Discussion
Michael A. Caligiuri
Carl H. June
Ari M. Melnick

 
Opening Reception
8-10 p.m.

Top of page

Saturday, June 23  

Continental Breakfast
7-8 a.m.


Concurrent Sessions 1-2
7:15-8 a.m.

Concurrent Session 1: Canine Lymphoma as a Surrogate for   Human Lymphomas: What Can We Learn from Canine Clinical Trials?
Session Cochairs: Luca Aresu, Department of Veterinary Science, Turin, Italy, and Kristy L. Richards, Cornell University, Ithaca, New York

Panel Discussion
Luca Aresu
Cheryl A. London, Tufts Medical Center, Boston, Massachusetts
Laura Marconato, Centro Oncologico Veterinario, Sasso Marconi, Italy
Kristy L. Richards


Concurrent Session 2: What Is the Optimal Therapeutic   Approach to NHL in Adolescents and Young Adults?: A Discussion from the Pediatric and Adult Perspectives
Session Chair: Lisa G. Roth, Weill Cornell Medical College, New York-Presbyterian Hospital, New York, New York

Panel Discussion
Kieron Dunleavy, George Washington University, Washington, D.C.
Lisa G. Roth


Plenary Session 1: Are We Ready for Lymphoma MATCH Trials? 
Session Chair: Anas Younes, Memorial Sloan Kettering Cancer Center, New York, New York
8-10:30 a.m.

Precision medicine based on the genetic taxonomy of DLBCL
Louis M. Staudt, National Cancer Institute, Bethesda, Maryland

How to design a MATCH trial for lymphoma
Anas Younes

Practical considerations for using genome sequencing data for patient selection
David W. Scott, BC Cancer Agency, Vancouver, BC, Canada

Molecular typing in DLBL: Sub-set and match?
Peter W. M. Johnson, University of Southampton, Southampton, United Kingdom 

Utilizing genomic sequencing from clinical assays in lymphoma management
Connie Batlevi, Memorial Sloan Kettering Cancer Center, New York, New York

Panel Discussion
Connie Batlevi
Peter W.M. Johnson
David W. Scott
Louis M. Staudt
Anas Younes


Break
10:30-11 a.m.


Spotlight on Proffered Papers Session 1
11-11:30 a.m.
(from posters in Session A)

Drugs in the curative RCHOP combination exhibit low cross-resistance but not pharmacologic synergy
Adam C. Palmer, Harvard Medical School, Boston, Massachusetts

MHC class II expression is associated with a distinct mutational profile and immune cell landscape of the microenvironment in GCB-DLBCL
Daisuke Ennishi, BC Cancer Agency, Vancouver, BC, Canada


Poster Session A/Lunch

11:45 a.m.-1:45 p.m.


Plenary Session 2: Targeting the Epigenome of DLBCL 
Session Cochairs: Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland, and Laura Pasqualucci, Columbia University Institute for Cancer Genetics, New York, New York
2-4 p.m.

DNA and histone methylation as therapeutic targets in lymphoma
Ari M. Melnick, Weill Cornell Medical College, New York, New York

Targeting EZH2 in lymphoma
Vincent Ribrag, Institut Gustave-Roussy, Villejuif, France

Germinal center-derived lymphomas: At the intersection of genetics and epigenetics
Laura Pasqualucci

BET inhibitors in lymphoma
Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland

Panel Discussion
Francesco Bertoni
Ari M. Melnick
Laura Pasqualucci
Vincent Ribrag


Break

4-4:30 p.m.


Plenary Session 3: Can Liquid Biopsies Replace Tissue and Be Used to Guide Clinical Decisions?
Session Chair: Davide Rossi, Università degli Studi del Piemonte Orientale, Vercelli, Italy
4:30-6:30 p.m.

Circulating tumour DNA to monitor treatment response and detect resistant clones in indolent lymphoproliferative diseases treated with novel therapies
Constantine S. Tam, Peter MacCallum Cancer Center, East Melbourne, VIC, Australia

Tumor fingerprints in the liquid biopsy: Immunoglobulin gene rearrangement or CAPP-seq?
Wyndham H. Wilson, National Cancer Institute, Bethesda, Maryland

Use of circulating tumor DNA to genotype aggressive lymphomas
Davide Rossi

Panel Discussion
Lee M. Greenberger, The Leukemia & Lymphoma Society, Rye Brook, New York
Davide Rossi
Constantine S. Tam
Wyndham H. Wilson


Dinner on Own
6:30 p.m.-

Top of page

Sunday, June 24 

Continental Breakfast
7-8 a.m.

Concurrent Sessions 3-4
7:15-8 a.m. 

Concurrent Session 3: What is the Current Role and Impact of   CRISPR Screening to Define Therapeutic Targets in Lymphoma? Session Chair: Hans-Guido Wendel, Memorial Sloan Kettering Cancer Center, New York, New York

Using in vivo CRISPR-based screening to identify lymphoma drug targets
Michael T. Hemann, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

Title to be announced
Sandeep S. Dave, Duke University, Durham, North Carolina

Crispr-Cas9 screens interrogate lymphoma biology and lead to therapies
Hans-Guido Wendel


Concurrent Session 4: Genetic and Molecular Heterogeneity Between Western and Asian Lymphoma Patients

Session Chair: Wei-Li Zhao, Ruijin Hospital, Shanghai Institute of Hematology, Shanghai, China

Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma: Insights for novel targeted therapies
Qiang Pan-Hammarström, Karolinska Institute, Stockholm, Sweden

The genetics of marginal zone lymphomas
Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland

Precise classification and treatment of NK/T and T-cell lymphoma
Wei-Li Zhao


Plenary Session 4: Will CAR T Cells Replace BMT as a Modality for NHL?  
Session Chair: Renier J. Brentjens, Memorial Sloan Kettering Cancer Center, New York, New York
8-10:30 a.m.   

Contemporary salvage therapy and autologous transplantation for relapsed and primary refractory DLBCL: The low bar has been firmly set
Craig S. Sauter, Memorial Sloan Kettering Cancer Center, New York, New York

Clinical overview of CAR T cell therapy in relapsed/refractory diffuse large B cell lymphoma: Promise and limitations
Michael R. Bishop, University of Chicago, Chicago, Illinois

Next-gen T cells
Renier J. Brentjens

CARS versus autos or CARS plus autos?
Stephen J. Forman, City of Hope, Duarte, California

Panel Discussion
Michael R. Bishop
Renier J. Brentjens
Stephen J. Forman
Craig S. Sauter

Break
10:30-11 a.m.


Spotlight on Proffered Papers Session 2

11-11:30 a.m.
(from posters in Session B)

Lenalidomide treatment restores in vivo T-cell activity in relapsed/refractory FL and DLBCL
Cedric Menard, University of Rennes, Rennes, France

Anti-CD37 chimeric antigen receptor T cells: A new potential therapeutic option for non-Hodgkin lymphoma
Irene Scarfo, Massachusetts General Hospital Cancer Center, Charlestown, Massachusetts


Poster Session B/Lunch
11:45 a.m.-1:45 p.m.


Plenary Session 5: The Significance of Targeting the   Microenvironment in Lymphoma
Session Chair: Irene M. Ghobrial, Dana-Farber Cancer Institute, Boston, Massachusetts
2-4 p.m.

Ex vivo lymphoid tissue microenvironments to model epigenetics and signaling in healthy and malignant B cells
Ankur Singh, Cornell University, Ithaca, New York

Dissecting microenvironmental cues that promote B cell lymphoma growth in secondary lymphoid organs
Uta E. Höpken, Max-Delbrück-Center for Molecular Medicine, Berlin, Germany

Targeting cancer-associated fibroblasts to promote anti-tumor immunity
Hélène Salmon, Icahn School of Medicine at Mount Sinai, New York, New York

Panel Discussion
Uta E. Höpken
Hélène Salmon
Ankur Singh


Break
4-4:30 p.m.


Plenary Session 6: Follicular Lymphoma: When to Treat and
How to Define Early Disease
Session Chair: Bertrand Nadel, Centre d'Immunologie de Marseille-Luminy, Marseille, France
4:30-6:30 p.m.

Committed Precursor cells (CPC) and follicular lymphoma genesis
Bertrand Nadel

Early treatment strategies to eradicate precursor clones
Michael R. Green, The University of Texas MD Anderson Cancer Center, Houston, Texas

Insights into early and late steps of follicular lymphoma pathogenesis from genomic studies
Robert Kridel, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Front-line chemotherapy-free treatments for follicular lymphoma?
Emanuele Zucca, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland

Panel Discussion
Michael R. Green
Robert Kridel
Bertrand Nadel 
Emanuele Zucca


Dinner on Own
6:30 p.m.-

Top of page

Monday, June 25  

Continental Breakfast
7-8 a.m.

Concurrent Sessions 5-6
7:15-8 a.m.

Concurrent Session 5: What is the Molecular Basis and Most Promising Road Towards Molecular Targeted Therapies for Double-Hit Lymphoma?
Session Chair: David M. Weinstock, Dana-Farber Cancer Institute, Boston, Massachusetts

The laboratory challenge of double-hit lymphoma
David M. Weinstock

The clinical challenge of double-hit lymphoma
Philippe Armand, Dana-Farber Cancer Institute, Boston, Massachusetts

Panel Discussion
Philippe Armand
David M. Weinstock


Concurrent Session 6: What do Mutation Profiles Teach Us   About Rare Versus Common Forms of Lymphoma?

Session Chair: Sandeep S. Dave, Duke University, Durham, North Carolina

Rare vs. common: Using genomic discoveries for a unified view of lymphoma
Sandeep S. Dave

Pathways to clinical translation of genetic discoveries
Eric D. Hsi, The Cleveland Clinic, Cleveland, Ohio

Panel Discussion
Sandeep S. Dave
Eric D. Hsi


Plenary Session 7: How Do Clonal Dynamics and Tumor   Heterogeneity Factor into Clinical Outcome and Therapy?
Session Chair: Dan A. Landau, Weill Cornell Medical College, New York, New York
8-10:30 a.m.

3’-UTR disruption of PD-L1 in malignant lymphomas
Seishi Ogawa, Kyoto University Graduate School of Medicine, Kyoto, Japan

Actionable molecular heterogeneity in DLBCL
Bjoern Chapuy, Dana-Farber Cancer Institute, Boston, Massachusetts

Epigenetic determinants of normal and malignant somatic evolution
Dan A. Landau

Ibrutinib does not suppress clonal evolution in high-risk chronic lymphocytic leukemia
Davide Rossi, Oncology Institute of Southern Switzerland and Institute of Oncology Research, Bellinzona, Switzerland

Genetic landscape of extranodal marginal zone (MALT) lymphomas
Francesco Bertoni, Institute of Oncology Research, Bellinzona, Switzerland

Panel Discussion
Francesco Bertoni
Bjoern Chapuy
Dan A. Landau
Seishi Ogawa
Davide Rossi


Break
10:30-11 a.m.


Spotlight on Proffered Papers Session 3
11-11:30 a.m.
(from posters in Session C)

HSF1 orchestrates a prolymphomagenic microenvironment through matrix remodeling and deficient lymphoma immunity
Jude M. Phillip, Weill Cornell Medicine, New York, New York

The ETS inhibitors YK-4-279 and TK-216 synergize with lenalidomide via SPIB downregulation in diffuse large B-cell lymphoma of the activated B cell-like type (ABC DLBCL)
Filippo Spriano, Institute of Oncology Research, Bellinzona, Switzerland


Poster Session C / Lunch
11:45 a.m.-1:45 p.m.


Plenary Session 8: What is the Role for Checkpoint Protein   Functionality and Therapeutic Blockade in Lymphoma?
Session Chair: Margaret A. Shipp, Dana-Farber Cancer Institute, Boston, Massachusetts
2-4 p.m.

Exploiting epigenetic and immune vulnerabilities in lymphoma
Ricky W. Johnstone, Peter MacCallum Cancer Center, Melbourne, Australia

Targetable genetic bases of immune evasion in lymphoma
Margaret A. Shipp

In situ vaccination for lymphoma
Ronald Levy, Stanford University, Stanford, California

Panel Discussion
Ronald Levy
Margaret A. Shipp


Break

4-4:30 p.m.


Plenary Session 9: Can We Improve the Outcome of Patients  with PTCL?
Session Chair: Kerry Savage, University of British Columbia, Vancouver, British Columbia, Canada
4:30-6:30 p.m.

How do we raise the therapeutic bar in PTCLs?
Kerry Savage

Genomics and genomic signatures in PTCLs
Wing C. Chan, City of Hope, Duarte, California

PDX models in T-cell lymphoma
David M. Weinstock, Dana-Farber Cancer Institute, Boston, Massachusetts

Novel drug combinations
Neha Mehta-Shah, Washington University Medical School, St. Louis, Missouri

Panel Discussion
Wing C. Chan
Neha Mehta-Shah
Kerry Savage
David M. Weinstock


Dinner on Own

6:30 p.m.-


Top of page

Tuesday, June 26 

Continental Breakfast
7-8 a.m.


Keynote Address 
8-10 a.m.

Keynote Address: Immune checkpoint blockade in cancer therapy: New insights, opportunities, and prospects for cures
James P. Allison, The University of Texas MD Anderson Cancer Center, Houston, Texas

Keynote Address: Targeting Achilles heels in multiple myeloma
Kenneth C. Anderson, Dana-Farber Cancer Institute, Boston, Massachusetts

Panel Discussion
James P. Allison
Kenneth C. Anderson
Ari M. Melnick


Break
10-10:15 a.m.


Plenary Session 10: Transforming First-line Therapy for Hodgkin and Non-Hodgkin Lymphoma
Session Chair: Thomas E. Witzig, Mayo Clinic College of Medicine, Rochester, Minnesota
10:15 a.m.-12:15 p.m.

Standard of care in 2018 for DLBCL: Setting the stage for the next NCTN trials
Thomas E. Witzig

Transforming the front-line Care of PTCL
Owen A. O'Connor, Columbia University Medical Center, New York, New York

Title to be announced
Kerry Savage, University of British Columbia, Vancouver, BC, Canada

Panel Discussion
Owen A. O'Connor
Kerry Savage
Thomas E. Witzig


Meeting Highlights: Promise for the Future
12:15-12:30 p.m.

Ari M. Melnick, Weill Cornell Medical College, New York, New York

Top of page